Freenome Reports Updated Clinical Validation Data for SimpleScreen CRC Blood Test
Freenome, Inc. (FRNM) reported clinical validation results for an updated version of its SimpleScreen CRC blood test. The updated screening test demonstrated 80.4% sensitivity for colorectal cancer at a 90% specificity rate. In addition, detection rates for advanced precancerous lesions increased to 18.2%, up from 13.7% in earlier data, while sensitivity for high-grade dysplasia reached 41.9%, up from 30.5%.
The performance gains across precancerous lesion subtypes enhance the test's ability to identify early-stage risk compared to earlier iterations. A higher detection rate for high-risk lesions strengthens the clinical argument for blood-based screening in early cancer prevention. Freenome previously received clearance from the U.S. Food and Drug Administration for its first-generation test, which launched commercially in September 2026 in partnership with Abbott.
Investors and medical providers will monitor whether Freenome secures regulatory clearance, formal clinical guideline inclusions, and expanded insurance coverage for the updated version. Commercial adoption and sales traction through Abbott's distribution network will also be key indicators to track. Shares of Freenome were trading at 15.78 USD, down 0.19% following the announcement.
Key points
- Freenome's updated SimpleScreen CRC blood test demonstrated 80.4% colorectal cancer sensitivity at 90% specificity.
- Detection for advanced precancerous lesions improved to 18.2%, compared to 13.7% in previous data.
- Sensitivity for high-grade dysplasia precancerous lesions rose to 41.9%, up from 30.5% in prior testing.
- The company commercializes its FDA-cleared blood test platform through a partnership with Abbott.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were the validation results for Freenome's updated CRC blood test?
The updated SimpleScreen CRC blood test showed 80.4% sensitivity for colorectal cancer at 90% specificity, with advanced precancerous lesion sensitivity reaching 18.2% and high-grade dysplasia sensitivity at 41.9%.
When did Freenome launch its first-generation CRC blood test?
Freenome launched its FDA-cleared first-generation SimpleScreen CRC blood test in September 2026 through its commercial partnership with Abbott.
How does Freenome distribute its SimpleScreen CRC test?
Freenome distributes and commercializes the SimpleScreen CRC blood test through its distribution partnership with Abbott.